## The IMPACT study: InforMing the PAthway of COPD Treatment<sup>1</sup>



Trelegy Ellipta is not approved for use anywhere outside the US.

### **IMPACT** in numbers<sup>1,2</sup>

centers worldwide

**37** countries

52 weeks

22

52

Around **10,000 COPD** patients randomized Approx **1,070 study** 

### **GSK's latest COPD study**

- One of the largest phase III pre-registration COPD studies ever conducted
- The first study to compare three different classes of COPD medications with the same molecules in the same inhaler type and with the same dosing frequency
- Will expand the evidence base for GSK's broad portfolio of once-daily treatments delivered via the Ellipta inhaler



### Single inhaler triple therapy

Trelegy Ellipta, a single inhaler triple therapy combination fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), is an approved treatment for COPD that provides an ICS, a LAMA and a LABA as a single once-daily inhalation.




All treatments administered **once daily** via the **Ellipta inhaler** 

COPD: chronic obstructive pulmonary disease LAMA: long-acting muscarinic receptor antagonis LABA: long-acting ß2-adrenergic receptor agonis ICS: inhaled corticosteroid

### Study design<sup>1</sup>

IMPACT was a phase III, randomised, double-blind, three-arm, parallel-group, global multicenter study comparing the rate of moderate and severe exacerbations between FF/UMEC/VI (Trelegy) and FF/VI (Breo) or UMEC/VI (Anoro) over 52 weeks:



At study entry

### Key inclusion criteria:<sup>1</sup>

- Patients ≥40 years
- Established clinical history of COPD
- Spirometry confirmed COPD diagnosis
- 2-week run-in on current treatmer



# Key exclusion criteria:<sup>1</sup>

- Pregnancy
- Current diagnosis of asthma or other respiratory disorders/risk factors
- Alpha1-antitrypsin deficiency as cause of COPD
- Other diseases or abnormalities as specified

ALB/SAL = albuterol/salbutamol; BD = bronchodilator; FEV, = forced expiratory volume in 1 second; FVC = forced vital capacit

**AND** either:

### Primary endpoints<sup>1</sup>



Annual rate of on-treatment moderate and severe exacerbations for:

- Trelegy vs Anoro
- Trelegy vs Relvar/Breo

### Other endpoints<sup>1</sup>



Change in FEV<sub>1</sub> for Trelegy vs Breo



Annual rate of on-treatment moderate and severe exacerbations for Trelegy vs Anoro in patients with blood eosinophil count ≥150 cells/µL



Change in quality of life as measured by SGRQ for Trelegy vs Breo



Annual rate of on-treatment severe exacerbations for Trelegy vs Anoro and vs Breo

**1** Safety assessments including:

- Incidence of adverse events
- Incidence of pneumonia
- Incidence of cardiovascular events



Time to first on-treatment moderate or severe exacerbation for Trelegy vs Anoro and vs Breo

SGRQ = St George's Respiratory Questionnaire

### References

- 1. Pascoe SJ, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Resp J 2016;48:320–330.
- ClinicalTrials.gov. A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
  - Available at: https://clinicaltrials.gov/ct2/show/record/NCT02164513. Last accessed: August 2017.

Ellipta, Relvar, Breo and Anoro are registered Trade Marks of Glaxo Group Limited.